English | Español

Bristol-Myers Squibb
Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients
Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending
+ Community
Patient Daily | Apr 17, 2025

ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+ Pharmaceuticals
Patient Daily | Apr 17, 2025

UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+ Pharmaceuticals
Patient Daily | Apr 22, 2025

National Consumers League CEO: 340B program abuse is 'a financial bonanza for non-profit hospitals'
+ Pharmaceuticals
Patient Daily | Apr 23, 2025

Empower Pharmacy CEO on pharmaceutical industry pricing disparities: 'Is it fair to charge one person in another country 10 times more?'